deltatrials
Completed PHASE4 INTERVENTIONAL 2-arm NCT02586623

Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension (RESTORE)

RESTORE: A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy

Sponsor: H. Lundbeck A/S

Conditions Symptomatic Neurogenic Orthostatic Hypotension
Interventions Droxidopa capsules Placebo capsules
Updated 15 times since 2017 Last updated: Aug 21, 2023 Started: Feb 11, 2016 Primary completion: Jul 21, 2022 Completion: Sep 9, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02586623, this PHASE4 trial focuses on Symptomatic Neurogenic Orthostatic Hypotension and remains completed. Sponsored by H. Lundbeck A/S, it has been updated 15 times since 2016, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Oct 2017 · 7 months · monthly snapshot~Oct 2017 – ~Jun 2018 · 8 months · monthly snapshot~Jun 2018 – ~May 2019 · 11 months · monthly snapshot~May 2019 – ~Jun 2020 · 13 months · monthly snapshot~Jun 2020 – ~Jan 2021 · 7 months · monthly snapshot~Jan 2021 – ~Jan 2022 · 12 months · monthly snapshot~Jan 2022 – ~Jul 2022 · 6 months · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Sep 2023 · 12 months · monthly snapshot~Sep 2023 – ~Jul 2024 · 10 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

15 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE4

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE4

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  4. Sep 2023 — Jul 2024 [monthly]

    Completed PHASE4

  5. Sep 2022 — Sep 2023 [monthly]

    Completed PHASE4

    Status: Active Not Recruiting → Completed

▶ Show 10 earlier versions

  1. Jul 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE4

    Status: Recruiting → Active Not Recruiting

  2. Jan 2022 — Jul 2022 [monthly]

    Recruiting PHASE4

  3. Jan 2021 — Jan 2022 [monthly]

    Recruiting PHASE4

  4. Jun 2020 — Jan 2021 [monthly]

    Recruiting PHASE4

  5. May 2019 — Jun 2020 [monthly]

    Recruiting PHASE4

  6. Jun 2018 — May 2019 [monthly]

    Recruiting PHASE4

  7. Oct 2017 — Jun 2018 [monthly]

    Recruiting PHASE4

  8. Mar 2017 — Oct 2017 [monthly]

    Recruiting PHASE4

  9. Feb 2017 — Mar 2017 [monthly]

    Recruiting PHASE4

  10. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE4

    First recorded

Feb 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • H. Lundbeck A/S
Data source: H. Lundbeck A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alexandria, United States , Apex, United States , Ardmore, United States , Atlanta, United States , Augusta, United States , Avon, United States , Bellevue, United States , Berkeley, United States , Bethlehem, United States , Boca Raton, United States and 95 more locations